8229 Boone Boulevard, Suite 802
Vienna, VA 22182
Phone: (703) 506-9460
Key Highlights of CEL-SCI-Corporation
CEL-SCI Corporation (“CEL-SCI” or “the Company”) is a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune and infectious diseases. The Company is targeting novel therapy candidates that activate and utilize the body’s own immune system against disease. CEL-SCI is developing products based on two technologies: (1) Multikine® (Leukocyte Interleukin, Injection), a novel immunotherapy first-line treatment that has completed a 10 year Phase 3 trial for head and neck cancer; and (2) LEAPS™ (Ligand Epitope Antigen Presentation System), an immunotherapy peptide vaccine technology platform. The goal of Multikine® is to modulate the body’s immune system to create a two-pronged mechanism of action: eliciting the direct killing of tumor cells and micrometastasis while generating a sustainable anti-tumor response to extend survival. Multikine® is being developed for neoadjuvant (before surgery) administration and could become an integral first-line component of the standard of care (SOC) regimen for locally advanced primary (previously untreated) head and neck cancers. As a neoadjuvant, Multikine® can stimulate the immune system before it is weakened by the toxic cancer therapies, improving its long-term therapeutic effect. The LEAPS™ platform is designed to stimulate the immune system to fight bacterial, viral, and parasitic infections more effectively, as well as autoimmune conditions (e.g., rheumatoid arthritis) and cancer. LEAPS™ can be designed to produce a specific natural immune response required for the desired therapeutic effect, depending on the type of LEAPS™ construct used.
* The Corporate Snapshot was last updated on March 20, 2023.